HEXIM1 and triple-negative breast carcinoma: HEXIM1 has been identified as a tumor suppressor, and reducing its level of expression has appeared to be associated with resistance to tamoxifen in breast tumors [86], anti-androgens in prostate cancer [87], and increased progression and decreased therapeutic sensitivity in triple-negative breast cancer [88].